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The reversibility of ubiquitination by the action of deubiquitinat-
ing enzymes (DUBs) serves as an important regulatory layer within
the ubiquitin system. Approximately 100 DUBs are encoded by the
human genome, and many have been implicated with pathologies,
including neurodegeneration and cancer. Non-lysine ubiquitina-
tion is chemically distinct, and its physiological importance is
emerging. Here, we couple chemically and chemoenzymatically syn-
thesized ubiquitinated lysine and threonine model substrates to a
mass spectrometry-based DUB assay. Using this platform, we profile
two-thirds of known catalytically active DUBs for threonine esterase
and lysine isopeptidase activity and find that most DUBs demon-
strate dual selectivity. However, with two anomalous exceptions,
the ovarian tumor domain DUB class demonstrates specific (iso)pep-
tidase activity. Strikingly, we find the Machado–Joseph disease
(MJD) class to be unappreciated non-lysine DUBswith highly specific
ubiquitin esterase activity rivaling the efficiency of the most active
isopeptidases. Esterase activity is dependent on the canonical cata-
lytic triad, but proximal hydrophobic residues appear to be general
determinants of non-lysine activity. Our findings also suggest that
ubiquitin esters have appreciable cellular stability and that non-
lysine ubiquitination is an integral component of the ubiquitin sys-
tem. Its regulatory sophistication is likely to rival that of canonical
ubiquitination.
ubiquitin | DUBs | non-lysine ubiquitination
Ubiquitination impacts on almost all cellular processes and iscarried out by a multienzyme cascade involving E1 activat-
ing enzymes (E1s), E2 conjugating enzymes (E2s), and E3 ligases
(E3s) (1, 2). E3s confer substrate specificity and can broadly be
classified into two main classes. The largest class consists of
RING E3s which use an adapter-like mechanism to facilitate di-
rect transfer of ubiquitin (Ub) from thioester-linked E2 (E2∼Ub)
to substrate (3). On the other hand, engagement of E2∼Ub by
HECT-like E3s results in formation of a thioester-linked E3 in-
termediate that carries out substrate transfer autonomously (4, 5).
Conventionally, Ub is linked to the e-amino group of lysine side
chains by an isopeptide bond, or, less frequently, it can be
appended to the α-amino group of proteins via a regular peptide
bond (1). Multiple residues within Ub itself can also become
ubiquitinated, allowing the formation of Ub polymers with distinct
linkage topologies that can mediate different cellular processes
(6). Ubiquitination is a dynamic modification and is reversed by
the action of deubiquitinating enzymes (DUBs). Approximately
100 DUBs have been identified in humans and are assigned to
seven distinct classes (7). For the majority of DUBs, substrate
specificity is poorly understood, with most biochemical insights
gained thus far coming from studies toward isopeptide-linked Ub
polymers. Alterations in substrate ubiquitination are often the
molecular basis for pathology, and DUBs have become attractive
therapeutic targets (7).
Although ubiquitination is typically a lysine-specific post-
translational modification, the RING E3 MIR1 encoded by
Kaposi’s sarcoma associated-herpes virus can evade host im-
mune responses by carrying out ubiquitination of cysteine within
major histocompatibility complex class I (MHC-I) molecules
(8, 9). This promotes their endocytosis and lysosomal degradation.
It was subsequently shown that MIR1 from murine γ-herpes virus
also ubiquitinates MHC-I molecules but targets serine, threonine,
and lysine residues and promotes their degradation by endoplas-
mic reticulum-associated degradation (ERAD) (10). However, the
adapter-like mechanism demonstrated by RING E3s relies upon
the active site of the E2 to mediate transfer chemistry. This grants
E2s with the important ability to direct ubiquitination to specific
sites within a substrate (1, 11). It was subsequently demonstrated
that murine MIR1 functions with the poorly studied mammalian
E2 UBE2J2, which was shown to possess cellular serine/threonine
esterification activity (12).
In further support of the physiological importance of non-lysine
ubiquitination, HECT-like E3s also possess intrinsic esterification
activity. MYCBP2/Phr1 has important roles in neural develop-
ment and programmed axon degeneration (13) and has highly
selective threonine esterification activity (5). Furthermore, the
E3 HOIL-1 has fundamental roles in immune signaling (14) and
forms ester linkages with serine/threonine residues within Ub
polymers and protein substrates (15). However, the cellular sta-
bility of Ub esters is unknown so it is not clear whether
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ubiquitination of hydroxy amino acids can serve as a sustained
cellular signal or if it is restricted to transient roles.
The emerging evidence that non-lysine ubiquitination has
important roles across a range of fundamental cellular process,
such as viral infection, ERAD, axon degeneration, and immune
signaling, places urgent emphasis on establishing which of the
∼100 DUBs might confer Ub esterase activity and serve as
negative regulators of this distinct form of ubiquitination. A
small panel of DUBs have been tested for activity against an
ester-linked substrate which indicated that certain DUBs do
possess esterase activity and this need not be mutually exclusive
with isopeptidase activity (16). However, comprehensive, DUB
profiling, across multiple classes, remains to be carried out.
Here, we synthesize model substrates consisting of threonine/
serine that are ester-linked to Ub. Using a high-throughput matrix-
assisted laser desorption/ionization time-of-flight (MALDI-TOF)
DUB assay (17), we profile two-thirds of known active Ub DUBs
for selectivity toward linkage chemistry (lysine isopeptide versus
threonine ester). Our findings show that the vast majority of
DUBs demonstrate isopeptidase and esterase activity with com-
parable kinetics. Isopeptidase versus esterase activity is largely
inherent to DUB class as ubiquitin-specific protease (USP) and
ubiquitin C-terminal hydrolase (UCH) DUBs displayed little
preference for linkage chemistry whereas ovarian tumor domain
(OTU) DUBs were largely dedicated isopeptidases. Two excep-
tions were TRABID and the virally encoded DUB, vOTU.
Strikingly, the Machado–Joseph disease (MJD) class demon-
strated selective threonine and serine esterase activity. We show
that esterase selectivity is maintained toward model peptide sub-
strates. Importantly, we also establish that Ub esters can have an
intracellular half-life of at least 1 h. We also demonstrate that,
in vitro, the E2 UBE2J2 possesses selective esterification activity,
as inferred by its auto modification profile, which is specifically
reversed by the MJD member JOSD1. Using chemically synthe-
sized fluorescent substrates, we quantify the catalytic efficiency of
JOSD1 and find it to be a highly efficient Ub esterase (kcat/KM =
3.5 × 104 M−1·s−1), an efficiency comparable to that of the most
efficient isopeptidases. While we could only quantify catalytic ef-
ficiency for threonine esterase activity, complementary assays
suggest JOSD1 serine esterase activity is considerably higher.
Taken together, our findings further support the biological sig-
nificance of non-lysine ubiquitination and demonstrate that its
regulatory sophistication is comparable to that of canonical
ubiquitination. The complementary activity profiles of certain
OTU DUBs with that of JOSD1 might also allow them to be used
as research tools for dissecting the emerging prevalence of non-
lysine substrate ubiquitination. Our ester-linked model substrates
should also facilitate the development of robust assays for inhib-
itor screening against MJD members.
Results
DUB Esterase and Isopeptidase Activity Profiling. To determine
DUB activity and specificity toward either ester or isopeptide
bonds, we employed a previously developed MALDI-TOF DUB
assay (17) and the model substrates Ub-Lysine (Ub-Lys) and Ub-
Threonine (Ub-Thr) (Fig. 1 A and B). However, as ubiquitination
site context is typically variable, lysine vs. threonine specificity
could be mediated by extended DUB–substrate interactions,
which our model substrates would not be able to determine.
Consequently, in the context of a DUBs physiological substrate,
amino acid specificity might be different to that observed with
these model substrates. For similar reasons, these substrates would
not recapitulate the diverse architectures of polyUb species and
would not be able to evaluate DUB-mediated exo- or endo-
cleavage (7). Ub-Lys was chemically prepared using a modified
implementation of genetically encoded orthogonal protection
and activated ligation (GOPAL) technology (18) (SI Appendix,
Fig. S1). Ub-Thr was chemoenzymatically prepared using a
reconstituted E1-E2-E3 cascade based on the RING-Cys-Relay
E3 machinery from MYCBP2 (5) (SI Appendix, Fig. S2). For both
amino acid substrates, the α-amino group was acetylated, which
helped mirror the peptide context the model substrates were re-
flective of, and also prevented potential O-N acyl transfer of Ub-
Thr to a peptide-linked species (19).
We screened a panel of 53 recombinant DUBs belonging to all
seven known DUB families (Fig. 2 A and B) (7): USP, OTU,
UCH, JAB1/MPN/Mov34 metalloenzyme (JAMM), MJD, motif
interacting with Ub-containing novel DUB family (MINDY),
and zinc finger with UFM1-specific peptidase domain protein
(ZUFSP). DUBs were incubated with Ub-Lys and Ub-Thr, and,
as positive controls, they were also incubated with an alternative
Ub-derived substrate (either an isopeptide-linked diUb or Ub
with a C-terminal peptide-linked adduct) known to be processed
by the DUB under investigation (SI Appendix, Fig. S3 and Table
S1). However, for the DUBs JOSD1, OTU1, OTUD6A, and
OTUD6B, a readily accessible substrate which is cleaved hitherto
remains to be identified. For quantification and normalization
purposes, the ratio of the area of the substrate ion intensity
signal (Ub-Lys or Ub-Thr) and the area of the product signal
(Ub) were recorded and extrapolated to a standard curve,
based on defined substrate/product ratios, enabling calculation
of percent substrate cleavage (SI Appendix, Fig. S4). By com-
paring the percent of cleavage of Ub-Lys versus Ub-Thr as a
function of time, we determined activity and specificity toward
the two model substrates (Fig. 2B). In practice, fractional
cleavage was sometimes found to exceed 100%. This is because
DUB, which is absent when producing the standard curve, can
suppress the mass spectrometry (MS) signal of low abundance
Ub species (e.g., Ub-Lys or Ub-Thr after appreciable cleavage),
and data were not normalized for this phenomenon.
Esterase and Isopeptidase Selectivity Is Largely Inherent to DUB
Classification. We find that DUBs belonging to the USP and
UCH family in general cleave both Ub-Lys and Ub-Thr sub-
strates with comparable kinetics (Fig. 2B). The USPs are the
largest class, consisting of ∼60 members, whereas UCHs are a
smaller classification, consisting of only 4 members (7). The only
USPs with negligible activity toward either substrate are USP5
and USP12. However, lack of USP5 activity is anticipated as it is
only functional toward polyUb with an intact free Ub C terminus
(20). In the case of the UCH class, UCHL1 is found to only
cleave the isopeptide-linked substrate while UCHL3, UCHL5,
and BAP1 show no appreciable preference between the two
model substrates (Fig. 2B).
In contrast to USP and UCH classes, OTU family members
invariably demonstrate efficient lysine isopeptidase activity to-
ward our model substrate, but negligible threonine esterase ac-
tivity (Fig. 2B). Two notable exceptions are vOTU and TRABID.
In the context of this assay, TRABID demonstrates selective
threonine esterase activity whereas vOTU demonstrates robust
activity toward both substrates (Fig. 2B). The DUB vOTU is
encoded by the deadly human pathogen, Crimean Congo hem-
orrhagic fever virus. In addition to its ability to hydrolyze four
out of six tested isopeptide-linked Ub polymer types (21), it has
also been shown to have relaxed substrate scope as it removes
the ubiquitin-like modifier ISG15 (21). Thus, the observation
that vOTU demonstrates high isopeptidase and threonine es-
terase activity implies that relaxation of its substrate scope ex-
tends to Ub linkage chemistry and that non-lysine ubiquitination
may promote mammalian antiviral responses more broadly.
TRABID has been implicated with Wnt and immune signaling
(22, 23) and has efficient isopeptidase activity in the context of
Lys29- and Lys33-linked Ub polymers (18, 24). However, in our
assay, TRABID has negligible isopeptidase activity toward Ub-
Lys, consistent with that observed for other, albeit peptide-
linked, small molecule substrates (25). Thus, our observation
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that TRABID has high activity toward Ub-Thr implies that its
esterase activity is more promiscuous than its isopeptidase ac-
tivity, and hence a significant proportion of its physiological
substrates may in fact be non-lysine ubiquitination sites.
The MJD family is a small class of DUBs consisting of four
members (26). Unlike the other DUB classifications which are
found in all eukaryotes, MJD DUBs are absent in yeast and
might be reflective of a specific demand of higher eukaryotes.
Strikingly, with the exception of ATXN3L, all MJD DUBs dem-
onstrate preferential threonine esterase activity (Fig. 2B). This is
particularly notable for JOSD1 where isopeptidase activity is
negligible but quantitative cleavage of the Ub-Thr substrate is
observed after the first time point. Similarly, Josephin-2 (JOSD2)
cleaves both substrates but has a significant preference for the Ub-
Thr substrate over the lysine counterpart. ATXN3 also cleaves
Ub-Thr more efficiently than Ub-Lys whereas ATXN3L does not
demonstrate any notable substrate preference (Fig. 2B).
We also tested the recently discovered MINDY and ZUFSP
classes of DUB. The MINDY class consists of four members,
which demonstrate exo (cleaving from the distal end) activity
toward extended Lys48 linked Ub polymers (27). ZUFSP con-
sists of a single founding member (ZUFSP/ZUP1) and is specific
for Lys63-linked Ub polymers and is involved in DNA repair
(28–31). Consistent with activity of these DUBs being dependent
on polyUb linkage context, negligible activity was observed to-
ward either of our model isopeptide or ester-linked substrates
(Fig. 2B).
Unlike the other DUB classes identified thus far which are
cysteine isopeptidases/peptidases, the JAMM class of DUBs are
metalloproteases (26). Two of the six functional JAMM class
DUBs included in our panel are AMSH and AMSH-LP, which
have both been shown to have specific activity toward isopeptide-
linked Lys63 Ub polymers with comparable efficiency. Interest-
ingly, under the enzyme concentrations employed, AMSH displays
no detectable esterase nor isopeptidase activity toward the
model substrates whereas AMSH-LP is active against both
model substrates (Fig. 2B) (32).
Cellular Stability of Ubiquitin Esters. The cellular stability of a Ub
ester would determine whether posttranslational modification
via this linkage would be restricted to transient roles or whether
it might also serve as a sustained cellular signal. Intrinsic sus-
ceptibility to hydrolysis and the action of the highly efficient and
promiscuous esterase activity found in mammalian cells might
limit its cellular function to transient roles (33). To assess the
cellular stability of a serine residue esterified with Ub, we de-
vised an experiment. Here, we prepared an engineered E2∼Ub
conjugate (E2Ser∼Ub), linked via a serine ester (Fig. 2C), and
delivered it into cells via electroporation (Fig. 2D) (34, 35).
Strikingly, we found that the conjugate had a cellular half-life of
1 to 2 h and could still be detected after 8 h, thereby suggesting
that ubiquitination of hydroxy amino acids can serve as a sus-
tained cellular signal.
Validation of Selective USP and OTU Isopeptidase Activity.To validate the
activity profiles determined by the MALDI-TOF assay format, we
initially prepared a fluorescent model substrate where the α-amino
group of threonine is labeled with 5/6-carboxytetramethylrhodamine
(TAMRA) (Ub-Thr-TAMRA) (Fig. 3 A and B). The fluorescent
amino acid was linked to Ub via an ester bond using the chemo-
enzymatic strategy adopted earlier. For comparison, we used com-
mercially available isopeptide-linked Ub-Lys-TAMRA-Gly (Fig. 3C).
Esterase or isopeptidase activity, respectively, would cleave the fluo-













































































































Fig. 1. MALDI-TOF–based methodology for profiling DUB isopeptidase/esterase activity. (A) DUBs are incubated either with ubiquitin-lysine (Ub-Lys) or
ubiquitin-threonine (Ub-Thr). (B) Reactions are quenched by addition of TFA (2%), spotted on an AnchorChip 1536 target and analyzed by MALDI-TOF mass
spectrometry. DUB isopeptidase or esterase activity releases free lysine or threonine and generates native Ub (8565.76 Da) in a time-dependent manner. Ion
intensity ratios for peaks corresponding to Ub-Lys (8731.8 Da)/Ub-Thr (8709.6 Da) versus Ub (8565.76 Da) are used for qualitative assessment of % cleavage.
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Fig. 2. DUB esterase and isopeptidase screen by MALDI-TOF mass spectrometry and assessment of cellular ubiquitin ester stability. (A) Phylogenetic clas-
sification of deubiquitinating enzymes based on their catalytic domains. Only DUBs that are active and recognize ubiquitin are displayed. The vOTU (red)
catalytic domain exists within Protein L, which is encoded by Crimean–Congo hemorrhagic fever virus. DUBs annotated with a solid circle correspond to those
profiled for activity in this study. (B) A panel of 53 DUBs were tested for their activity toward model substrates Ub-Lys and Ub-Thr. Reactions were then
quenched by addition of TFA (2%) at the relevant time points and spotted onto a 1536 AnchorChip target plate, followed by MALDI-TOF analysis (17). Results
are reported as percent of cleavage in a scale from white (no activity) to dark blue (100% substrate consumption). Employed DUB concentrations are specified
in SI Appendix, Table S1. (C) An engineered E2∼Ub conjugate linked to the Ub C terminus via a serine ester (E2Ser∼Ub) was used as model ester-linked
substrate. Resistance to BME, but sensitivity to NaOH, is consistent with the conjugate being ester-linked. (D) E2Ser∼Ub was delivered into HEK293 cells by
electroporation and then transferred directly into prewarmed media and then incubated at 37 °C, 5% CO2. Samples were taken at the indicated time points
postelectroporation. The experiment was replicated in parallel, using HEK293 pretreated with 20 μM MG132 for 30 min, and cells incubated in media
containing MG-132 throughout.
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Fig. 3. Validation of selected DUB activity toward Ub-Lys-TAMRA-Gly and Ub-Thr-TAMRA by continuous FP-based assay, and ubiquitinated model lysine and
threonine peptides by gel-shift assay. (A) LC-MS characterization data for Ub-Thr-TAMRA: HPLC chromatogram for purified Ub-Thr-TAMRA monitoring at
214 nm, electrospray ionization mass spectrum for Ub-Thr-TAMRA and deconvoluted mass spectrum for Ub-Thr-TAMRA (theoretical mass = 9078.65; observed
mass = 9076 Da). (B) Chemical structure of the fluorescent Ub-Thr-TAMRA. (C) Chemical structure of commercial Ub-Lys-TAMRA-Gly. (D) Consistent with the
MALDI-TOF data, USP2 (0.125 μM) demonstrates comparable lysine isopeptidase and threonine esterase activity. (E) The virally encoded DUB, vOTU (1.5 μM),
has both lysine isopeptidase and threonine esterase activity with an apparent selectivity for the isopeptide-linked model substrate. (F–H) OTUD3, OTUB2, and
OTUD6A (1.5 μM) demonstrate selective lysine isopeptidase activity. (I) Inconsistent with the MALDI-TOF data using the simple model substrates Ub-Lys and
Ub-Thr, TRABID (1.5 μM) demonstrates both weak isopeptidase and esterase activity. (J) A subset of DUBs were buffer exchanged by dialysis to remove DTT.
To establish whether Ub-Glutathione cleavage was DUB-mediated, or due to thiolysis by residual DTT, the buffer the samples were dialyzed against was
added as a control. (K) To ascertain whether the observed DUB activity profiles were observed in a peptide context, activity was assessed toward unlabeled
ubiquitinated model peptides (Ub-EGKGN and Ub-EGTGN). Consistent with both MALDI-TOF data using unlabeled amino acid substrates and FP data using
TAMRA-labeled substrates, both USP2 and vOTU (0.75 μM) demonstrate robust isopeptidase and esterase activity. Consistent with the MALDI-TOF data
toward unlabeled Ub-Lys and Ub-Thr, TRABID (0.75 μM) demonstrates negligible lysine isopeptidase activity, but robust threonine esterase activity. For clarity,
the ubiquitinated amino acids in the peptides are highlighted in red.
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measurement of DUB activity by fluorescence polarization (FP) (36).
For orthogonal testing in the FP assay, we selected the USP class
DUBUSP2 and vOTU, both of which demonstrate high isopeptidase
and esterase activity (Fig. 2B). We also selected OTUB2, OTUD3,
and OTUD6A, which demonstrate isopeptidase specificity, and
TRABID, which demonstrates selective threonine esterase activity,
despite reports of it being an efficient isopeptidase (Fig. 2B). Under
these alternative assay conditions, USP2 maintains dual specificity,
with comparable observed rates for isopeptidase and threonine es-
terase activity (0.18 min−1 and 0.13 min−1, respectively) (Fig. 3D).
The DUB vOTU also maintains dual specificity, albeit with a pref-
erence for Ub-Lys-TAMRA-Gly (Fig. 3E). Again, consistent with the
MALDI-TOF assay, the OTU DUBs OTUD3, OTUB2, and
OTUD6A exhibit isopeptidase specificity as no threonine esterase
activity is detected (Fig. 3 F–H). However, despite demonstrating
threonine esterase activity toward the small acetylated threonine
substrate, TRABID is only weakly active against Ub-Thr-TAMRA
and, unexpectedly, similarly so toward the Ub-Lys-TAMRA-Gly
(Fig. 3I). To ascertain if the C-terminal glycine residue in the
isopeptide-linked substrate might be affecting the ability to
process the isopeptide-linked substrate, relative to the less hin-
dered Ub-Thr-TAMRA substrate, we also prepared an analo-
gous Ub-Lys-TAMRA substrate (SI Appendix, Fig. S5) and
found activity to be comparable toward both (SI Appendix, Fig.
S6). This is indicative of the TAMRA fluorophore present in
Ub-Thr-TAMRA interfering with recognition by TRABID.
Thioesterase Activity Is Possessed by DUBs with Isopeptidase and
Esterase Activity. It has been reported that ubiquitination can
also extend to cysteine residues where the linkage chemistry is a
thioester bond (9, 37). It remains unknown if DUBs can also
cleave this linkage chemistry. We attempted chemoenzymatic
preparation of simple model cysteine substrates (38), analogous
to those described above (Figs. 1 and 3), but found them to be
unstable by mass spectrometry as they would seemingly rear-
range to the peptide-linked cysteine adduct with concomitant
loss of the acetyl or TAMRA groups, presumably promoted by
the free cysteine carboxylate. We therefore sought an alternative
model cysteine-containing substrate and opted for reduced glu-
tathione. Ubiquitinated glutathione (Ub-Glutathione) was prepared
using a modification of a reported chemoenzymatic procedure (38)
(SI Appendix, Fig. S7). As expected, Ub-Glutathione could be
purified and was sufficiently stable for DUB activity analysis.
However, as our DUB preparations contained dithiothreitol
(DTT) reducing agent which would lead to thioester thiolysis, we
buffer-exchanged a subset of DUBs with distinct specificity
profiles into phosphate-buffered saline (PBS) containing the
phosphine-based reducing agent Tris(2-carboxyethyl)phosphine
(TCEP). This DUB subset was then tested for cysteine thio-
esterase activity using the MALDI-TOF assay (Fig. 3J). Al-
though the dialysis procedure compromised DUB activity, all
DUBs demonstrated Ub-Glutathione thioesterase activity simi-
lar to or greater than that toward their preferred isopeptide or
ester substrate (Fig. 3J).
TRABID Demonstrates Selective Threonine Esterase Activity toward a
Peptide Substrate. The unexpected esterase activity toward Ub-
Thr, and the inconsistent results obtained from this substrate and
Ub-Thr-TAMRA, prompted us to prepare alternative substrates
based on model peptides (Ac-EGXGN-NH2 where X = K or T)
that were either isopeptide-linked or ester-linked to Ub. DUB
activity toward these peptide substrates would be more reflective
of a native protein substrate and could be assessed by electro-
phoretic shift upon sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS-PAGE) analysis. Ubiquitinated peptides
were prepared using a reconstituted E1-E2-E3 cascade based on
a constitutively active RING E3 (RNF4) (39), or MYCBP2, and
were purified by reversed-phase high-performance liquid
chromatography (RP-HPLC) (SI Appendix, Figs. S8 and S9). We
initially tested USP2 and vOTU. Consistent with the activity
profiles toward the Ub-Lys and Ub-Thr substrates, USP2 and
vOTU cleaved both the isopeptide-linked and threonine-linked
peptide substrates within our first time point, supporting the
notion that the bispecific isopeptidase and esterase activity
demonstrated by the vast majority of USP DUBs and vOTU
would extend to protein substrates (Fig. 3K).
Consistent with the initial MALDI-TOF assay data using
nonfluorophore-labeled amino acid substrates, TRABID dem-
onstrated threonine esterase activity within the peptide context
but no lysine isopeptidase activity (Fig. 3K). This suggests that,
while TRABID has efficient isopeptidase activity toward distinct
polyUb linkages (18), it reinforces our earlier assertion that its
esterase activity is indeed more promiscuous and TRABID is
likely to have unappreciated substrates that are ester-linked
to Ub.
MJD DUBs Have Selective Ubiquitin Esterase Activity. The Machado–
Josephin family (also referred to as Josephins) are a small class of
DUBs consisting of four members (ATXN3, ATXN3L, JOSD1,
and JOSD2). The founding and most-studied member is Ataxin-3
(ATXN3) (40, 41). This protein is encoded by the gene respon-
sible for the neurological condition spinocerebellar ataxia type-3,
or Machado–Joseph disease, from which the MJD class takes its
name. Machado–Joseph disease is an autosomal dominant neu-
rodegenerative disorder caused by polyQ tract expansion (42). All
MJD proteins share a common globular catalytic cysteine protease
domain of ∼180 amino acids, known as the Josephin domain.
ATXN3 and ATXN3L sequences consist of the Josephin domain
and a disordered C-terminal tail where the polyQ tract and two or
three ubiquitin-interacting motifs (UIMs) are located. The latter bind
polyUb chains (Fig. 4A) (41, 43). JOSD1 and JOSD2, on the other
hand, consist of little more than the catalytic Josephin domain.
JOSD1 is implicated with membrane dynamics (44), cancer
chemoresistance (45), and antiviral response (46), yet its physi-
ological substrates are poorly defined (45, 46). It has been
reported that JOSD1 and ATXN3 can exist as monoubiquitinated
forms which have a modest activating effect on their ability to
cleave polyUb species (44, 47). Importantly, it has recently been
shown that elevated JOSD1 levels are found in gynecological
cancers and this correlates with poor prognosis (45). JOSD1 also
promotes chemoresistance by stabilizing antiapoptotic myeloid
cell leukemia 1 (MCL-1). We too observe a high molecular
weight form of JOSD1 when transiently overexpressed in
HEK293 cells (SI Appendix, Fig. S10). However, this was neither
sensitive to USP2 nor hydroxylamine treatment (SI Appendix,
Fig. S11). We could also immunologically detect JOSD1 in
various mouse tissues, with highest levels of expression observed
in the heart, liver, kidney, and spleen in mouse tissue lysates (SI
Appendix, Fig. S10). Although MJD DUBs have been shown to
have isopeptidase activity toward polyUb substrates, this has not
been quantified, and the qualitative data that do exist involve high
micromolar concentrations of DUB and/or lengthy incubation
times (e.g., 16 to 20 h) (44). To reconcile the sluggish isopeptidase
kinetics, it has been proposed that ATXN3 may serve as a cellular
timer (48). Another possibility is that the precise nature of the
physiological substrates is yet to be determined.
Our observation that MJD DUBs have potent threonine es-
terase activity raised the possibility they were an unappreciated
class of specific Ub esterase. To explore this possibility further,
we tested the four MJD DUBs for activity against the peptide
substrates. We also managed to prepare limiting amounts of a
substrate based on a serine peptide (Ac-EGSGN-NH2) using the
reconstituted MYCBP2 system (SI Appendix, Fig. S12). JOSD1
demonstrated highly specific threonine esterase activity in this
context (Fig. 4B). Strikingly, JOSD1 serine esterase activity was
found to be considerably higher than that toward threonine
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Fig. 4. Comprehensive assessment ofMJDDUB selective esterase activity toward peptides and the non-lysine automodification product of the E2 conjugating enzymeUBE2J2.
(A) Domain architecture ofMJD DUBs. (B, Top) Assessment of JOSD1 (1.5 μM) selective threonine esterase activity toward Ub-EGKGN and Ub-EGTGNmodel peptide substrates.
(B, Bottom) Comparison of JOSD1 (5 μM) activity toward Ub-EGSGN and Ub-EGTGN. (C) Assessment of JOSD2 (1.5 μM) selective threonine esterase activity toward model
peptide substrates. (D) Assessment of ATXN3 (1.5 μM) selective threonine esterase activity toward model peptide substrates. (E) Assessment of ATXN3L (1.5 μM) selective
threonine esterase activity toward model peptide substrates. Gels presented in B–E were visualized by silver staining. (F) MALDI-TOF assay data demonstrating that, with the
exception of ATXN3L, all MJD family members demonstrate selective threonine/serine esterase activity toward model Ub-Lys, Ub-Thr, and Ub-Ser substrates. (G) Enzymatic
reconstitution in PBS (pH 7.5) with UBE2J2 (20 μM), E1 (200 nM), Ub (50 μM), and ATP (2 mM). Reaction was incubated for 30 min at 37 °C, and E2 loading was terminated by
addition of Compound 1 E1 inhibitor (25 μM) (55). Samples were then treated with buffer control or DUB (3 μM) for 30 min at 30 °C. Reactions were terminated with SDS
loading buffer containing BME or BME plus hydroxylamine (0.5 M) and incubated for 30 min at 37 °C prior to SDS-PAGE analysis. (H) High and low exposures for anti-Ub
immunoblot (IB) of samples analyzed in G.
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(100% cleavage after first time point) (Fig. 4B). JOSD2 com-
pletely cleaved the threonine substrate within the first time point
but also demonstrated some lysine isopeptidase activity (Fig.
4C). ATXN3 demonstrated specific threonine esterase activity
whereas, for ATXN3L, isopeptidase activity was also discernible
(Fig. 4 D and E). These observations are distinct from those
observed with the MALDI-TOF screen employing Ub-Lys and
Ub-Thr substrates where JOSD2 and ATXN3L exhibited modest
or negligible selectivity, respectively. To confirm this was at-
tributable to the different substrates employed, we reassessed
JOSD2 and ATXN3L activity toward Ub-Lys and Ub-Thr using a
complementary electrospray mass spectrometry assay (SI Ap-
pendix, Fig. S13) (5). Here, we found that the selectivity profile is
similar to that observed with the MALDI-TOF assay, verifying
that the relaxed specificity is due to substrate context.
We also found that ATXN3 demonstrates considerably higher
esterase activity toward the serine peptide compared to the
threonine peptide (SI Appendix, Fig. S14). These findings imply
that all four MJD DUBs have highly selective, if not specific,
esterase activity toward our degenerate peptide substrates. Un-
fortunately, we could not prepare sufficient quantities of serine
peptide substrate to test all four MJD members so it remains a
possibility that JOSD2 and ATXN3L also demonstrate greater
serine esterase activity in a peptide context.
To assess whether, in principle, JOSD2 and ATXN3L also
have serine esterase activity, we chemoenzymatically prepared
the simple ubiquitinated serine substrate (Ub-Ser) in sufficient
yield for comparison of all MJD members using the MALDI-
TOF assay (SI Appendix, Fig. S15). Under the employed assay
conditions, the MJD class demonstrated both serine and threo-
nine esterase activity with comparable efficiency under the
employed conditions (Fig. 4F).
We next assessed whether JOSD1 esterase activity and speci-
ficity were maintained in a protein context. The lack of tools for
studying non-lysine ubiquitination precluded the development of
assays based on a physiological protein substrate. However, the
E2 conjugating enzyme UBE2J2 has been reported as having
esterification activity and undergoes auto modification in the
presence of E1, Ub, and adenosine 5′-triphosphate (ATP) (5,
12). The presence of ester linkages would allow the Ub-modified
E2 to be used as a model protein substrate of DUB esterase
activity. We therefore tested if the auto modifications were ester-
linked (5). Ester-linked conjugates were determined by assess-
ment of which were stable after 2-mercaptoethanol (BME)
treatment but were cleaved after combination treatment with
BME and hydroxylamine. Conjugates that were cleaved after
BME treatment would correspond to those that are thioester-
linked whereas those that persisted after combination treatment
would correspond to those that are isopeptide-linked. We found
that a predominant ester-linked Ub adduct is formed, together
with a minor (iso)peptide-linked adduct (Fig. 4 G and H).
Strikingly, when employed as a model substrate for JOSD1,
specific and quantitative esterase activity was observed (Fig. 4 G
and H). Furthermore, treatment with USP2 removed major and
minor bands, thereby validating our earlier findings that USP2
has both esterase and isopeptidase activity.
Quantification of JOSD1 Threonine Esterase Activity. We next bench-
marked JOSD1 threonine esterase activity against USP2 using
the FP assay with the fluorescent Ub-Lys-TAMRA-Gly and
Ub-Thr-TAMRA substrates. USP2 is a highly active DUB
(kcat/KM = ∼2.5 × 105 M−1·s−1) (49) and has been used as a
research tool to selectively remove Ub from cellular protein sub-
strates by presumed selective isopeptidase activity (50). Consistent
with mass spectrometry and gel-based assays, USP2 readily cleaved
Ub from Ub-Lys-TAMRA-Gly and Ub-Thr-TAMRA with similar
kinetics (Fig. 5 A and B). However, JOSD1 readily cleaved the
Ub-Thr-TAMRA substrate with an observed rate constant
comparable to that of USP2 (Fig. 5B) but exhibited no detectable
isopeptidase activity toward Ub-Lys-TAMRA-Gly (Fig. 5A). To
determine if the additional glycine residue in Ub-Lys-TAMRA-Gly
was affecting isopeptidase activity, we tested all MJD DUBs against
our synthesized Ub-Lys-TAMRA substrate and observed equiva-
lent cleavage kinetics (SI Appendix, Fig. S6).
To quantify the catalytic efficiency of JOSD1 esterase activity and
determine its catalytic parameters, we carried out Michaelis–
Menten analysis toward Ub-Thr-TAMRA (Fig. 5C). Catalytic
turnover [kcat is 0.36 (±0.02) s
−1] and the Michaelis constant [KM is
10.4 (±1.5) μM] are indicative of the observed esterase activity
being largely driven by kcat. The resultant specificity constant
[kcat/KM = 3.5 × 10
4 M−1·s−1] is comparable to that of USP21 for
the K48 Ub dimer (51), which is at the high end of the spectrum of
kinetically quantified DUB isopeptidase activity. It should be
noted that, on account of JOSD1 esterase activity being consid-
erably higher toward serine than threonine in our peptide-based
substrates (Fig. 4B), a much higher specificity constant might be
found with a serine substrate. Taken together, these findings are
consistent with JOSD1 having the potential to mediate dynamic
cellular deubiquitination via its esterase activity. JOSD2 also
demonstrated selective esterase activity (Fig. 5 D and E).
However, with these TAMRA-labeled substrates ATXN3 and
ATXN3L demonstrated negligible or undetectable activity,
respectively (Fig. 5 F and G).
JOSD1 Esterase Activity Is Mediated by the Canonical Catalytic Site.
The crystal structure of ATXN3, which has been solved in
complex with a Ub suicide substrate probe (48), allowed us to
build a high confidence homology model (99%) for JOSD1 with
Phyre2 (52). In the experimental structure, the active site resi-
dues are well resolved, and, although a substrate is absent, res-
idues that would be in immediate proximity of the modified
substrate amino acid can be approximated (Fig. 6 A and B). In
light of the unexpected esterase activity, we first determined
whether it was dependent on the established catalytic cysteine
within JOSD1 (Fig. 6 A and B). JOSD1 isopeptidase activity has
been shown to be dependent on C36 (44). We also found that a
C36A mutant of JOSD1 abolishes activity toward Ub-Thr-TAMRA
(Fig. 6C). Mutation of the histidine belonging to the catalytic triad
(H139) also abolishes activity (Fig. 6C). These results indicate that
the catalytic triad centering on C36 in JOSD1, and presumably the
homologous residue in other MJD class DUBs, mediates efficient
esterase activity.
Assessment of the Structural Basis for MJD DUB Esterase Activity. To
determine catalytic residues that might facilitate the selective
threonine esterase activity, we studied the experimental ATXN3-
Ub structure and its superposition with our JOSD1 homology
model (Fig. 6A). A conspicuous feature of the ATXN3 and
JOSD1 catalytic sites is their hydrophobic nature. The JOSD1
model places two tryptophan residues in the active site whereas
ATXN3 has two crystallographically determined phenylalanine
residues at the equivalent positions (Fig. 6 A and B). In some
JOSD1 orthologs, the residue equivalent to W101 is also a
phenylalanine, raising the possibility that the phenylalanine
residue can serve a similar function to the tryptophan (SI Ap-
pendix, Fig. S16). To test if the hydrophobic residues were con-
tributing to JOSD1 esterase activity, we mutated the tryptophan
residues and tested activity. Strikingly, W100Q and a W100N
mutation abolished activity, implying that hydrophobic character
is important (Fig. 6C). W100A and W101A mutations also
abolished JOSD1 esterase activity, indicating the aromatic na-
ture, shared by the phenylalanine residue found in JOSD1
orthologs and in ATXN3 and AXTN3L, may also be significant
(Fig. 6D). We next assessed whether the tryptophan and phe-
nylalanine residues might serve shared functions. We introduced
W100F and W101F mutations, either singularly or in
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combination, into JOSD1 (Fig. 6D). In support of a shared
function, threonine esterase activity of the W100F mutant was
modestly impaired whereas a W101F mutant retained wild-type
(WT) levels of activity. To test if the homologous phenylalanine
residues in ATXN3 might have similar function, we assayed al-
anine mutants in the MALDI-TOF and peptide-based gel shift
assays (SI Appendix, Figs. S16 and S17). While an ATXN3 F74A
mutant had no discernible effect on activity, an F75A mutant
abolished ATXN3 esterase activity, underscoring the functional
relevance of the second hydrophobic residue across the MJD
class. We also explored the effect of F74W and F75W mutations
on ATXN3 (SI Appendix, Fig. S16). No detectable activity was
observed for the F74W mutation, indicative of the tryptophan at
this position being incompatible in the context of the ATXN3
active site. The F75W mutant retains WT levels of activity,
suggestive of the phenylalanine residue in ATXN3 and the
tryptophan residue in JOSD1 having similar molecular function.
Discussion
Non-lysine ubiquitination is emerging as a physiologically im-
portant posttranslational modification. As systems-wide technolo-
gies for identifying ubiquitination sites are tailored for lysine
ubiquitination, the scale of cellular non-lysine ubiquitination re-
mains to be determined. We tested the activity of 53 DUBs against
both lysine and non-lysine ubiquitinated model substrates, making
the current work the most extensive and cross-validated study on
non-lysine DUB activity to date. The results show that isopeptidase
versus esterase activity is largely dependent on DUB phylogeny. We
found that, on the whole, USP and UCH class DUBs mediate both
isopeptidase and esterase activity with comparable kinetics. On the
other hand, the OTU DUB classification is largely devoid of es-
terase activity. Among the OTU members we studied, TRABID
and virally encoded vOTU were exceptions. Toward our model
substrates, vOTU demonstrated robust esterase and isopeptidase
activity whereas TRABID only conferred esterase activity. How-
ever, as TRABID has been shown to mediate efficient isopeptidase
activity toward Ub polymers, it would appear that it has the po-
tential to confer dual chemical substrate specificity within cells.
Most insights toward DUB substrates have been in the context of
polyubiquitin linkage preference. In comparison, knowledge of
physiological protein substrates is limited, and our findings imply
that non-lysine ubiquitination sites must be considered when
studying the majority of DUBs (USP, UCH, and MJD classes). We
also establish that, in principle, Ub esters can be relatively long-lived
inside cells, implying that ubiquitination of hydroxy amino acids can
serve as a sustained cellular signal.
The discovery that MJD DUBs, and JOSD1 in particular, have
selective Ub esterase activity was striking, suggestive of these
DUBs being dedicated to specifically editing non-lysine ubiquiti-
nated substrates. This is particularly evident from our observation
that JOSD1 maintains specific esterase DUB activity in the con-
text of the protein substrate UBE2J2. Furthermore, the molecular
basis for UBE2J2 esterification activity, and whether any of the
other ∼30 E2s might confer esterification activity, remain poorly
understood. The modular nature of the RING E3 catalytic
mechanism presents the possibility that, in principal, any of the
∼600 RING E3s could direct esterification of hydroxy amino acids
within substrates. This is in further support of the prevalence of
non-lysine ubiquitination being underestimated.
We identified features, within the MJD active site, that are crucial
for their activity. The presence of hydrophobic residues adjacent to
the catalytic cysteine appears to serve an important role in mediating
selective esterification and esterase activity. The precise role these
residues play might be further validated by structural studies. If such
hydrophobic residues present within the active site are a universal
feature of Ub cascade enzymes (E2s, E3s) that might also have non-
lysine activity, then, where structural data exists, this feature could
potentially be used to predict the existence of such enzymes.
Within the MJD family, ATXN3 represents the most well-
studied enzyme as it is related to the development of spinocer-
ebellar ataxia type-3, and its established esterase activity might
be of patho-physiological relevance. Within the MJD family,
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Fig. 5. Characterization of MJD DUB esterase activity by FP-based assay toward model amino acid substrates. (A) Ub-Lys-TAMRA-Gly tested at 250 nM. The
USP class DUB USP2 demonstrates efficient isopeptidase activity toward Ub-Lys-TAMRA-Gly whereas JOSD1 isopeptidase activity is undetectable. (B) JOSD1
demonstrates efficient esterase activity toward Ub-Thr-TAMRA with comparable kinetics to that of USP2. (C) Steady-state Michaelis–Menten analysis for
JOSD1 esterase activity toward Ub-Thr-TAMRA (JOSD1 assay concentration was 37 nM). (D) Negligible JOSD2 isopeptidase activity is also observed toward
Ub-Lys-TAMRA-Gly (note JOSD2 concentration is 1.25 μM). (E) JOSD2 is a less efficient esterase than JOSD1 toward Ub-Thr-TAMRA, but cleavage kinetics are
comparable when JOSD2 concentration is increased ∼30-fold relative to JOSD1. (F) ATXN3 esterase activity is negligible toward the synthetic Ub-Lys-TAMRA-
Gly substrate whereas ATXN3L exhibits weak isopeptidase activity. (G) Both ATXN3 and ATXN3L exhibit negligible esterase activity toward Ub-Thr-TAMRA.
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JOSD1 and JOSD2 represent the least studied members. De-
spite their sequence homology, JOSD1 and JOSD2 seem to have
distinct physiological functions and different catalytic efficien-
cies. JOSD2 has been found able to cleave ubiquitin chains
in vitro while JOSD1 has been reported as having low activity or
being inactive (44). These results are consistent with our finding
that JOSD2 shows some degree of activity against the isopeptide-
linked model-substrate. However, it should be noted that MJD
DUB activity toward isopeptide-linked substrates has not been
quantified.
The association of JOSD1 with the development of chemo-
resistance in gynecological cancer makes it the subject of a
potential biomarker and therapeutic target. However, devel-
oping a robust assay for screening JOSD1 inhibitors would
certainly be a challenge due to the low signal window obtained
with conventional (iso)peptide-linked substrates. The sub-
strates produced in our study, notably Ub-Thr-TAMRA, should
facilitate the development of valuable assay platforms for in-
hibitor screening of MJD DUBs, an emerging class of thera-
peutic targets. The presence of UIM domains in ATXN3 and
ATXN3L may have a significant effect on their cellular func-
tion. These could engage polyUb chains, thereby influencing
cellular localization, and could also enhance catalytic efficiency
through avidity effects. Furthermore, despite the striking
specificity and high catalytic efficiency of JOSD1 threonine
esterase activity, our data imply that catalytic efficiency toward
serine substrates could be greater still and require quantifica-
tion. Finally, the esterase activity conferred by MJD DUBs
might allow it to be used in combination with DUBs with se-
lective isopeptidase activity (e.g., OTUD3, OTUB2, and
OTUD6) for diagnosis of Ub linkage chemistry within cellular
substrates.
Materials and Methods
Ubiquitin monomer, bovine serum albumin (BSA), Tris, dimethyl sulfoxide
(DMSO), and DTT were purchased from Sigma-Aldrich. Ub-Lys-TAMRA-Gly
was purchased from Boston Biochem (Boston, MA) (no. U-558). MALDI-TOF MS
1536 AnchorChip was purchased from Bruker Daltonics (Bremen, Germany).
The 2′,6′-dihydroxyacetophenone (DHAP) matrix was purchased from
Tokyo Chemical Industry (product no. D1716). JOSD1 monoclonal antibody
was purchased from Thermo Fisher (MA5-25365).
Synthesis of Ub-Lys, Ub-Thr, and Ub-Glutathione Model Substrates. Ub-Lys was
prepared using a modification of GOPAL technology, which was developed
for the production of defined isopeptide-linked Ub chains (18). In brief, an
excess of Nα-acetyl-L-lysine was dissolved in DMSO together with a chemically pro-
tected Ub thioester protein in the presence of AgNO3 andN-hydroxysuccimimide as
catalyst. After incubation at 23 °C, protein was precipitated with ice-cold
diethylether and air-dried. Chemical protecting groups were removed as
previously described (18), and deprotected protein was isolated by ether
precipitation. Dried protein was dissolved in denaturing guanidinium chloride
buffer and purified by RP-HPLC (17). Fractions containing Ub-Lysine were de-
termined by liquid chromatography-mass spectrometry (LC-MS), freeze dried,
and stored at −20 °C. Prior to DUB analysis, freeze-dried Ub-Lysine was dis-
solved in the minimum volume of DMSO. Protein folding was then initiated by
the addition of 9 volume equivalents of PBS (53). This procedure was used to
refold all model Ub substrates, and final concentration ranged from 0.8 to
3.0 mg/mL. For long-term storage, samples were aliquotted, frozen in liquid
N2, and kept at −80 °C. Minor hydrolysis (∼10%) of ester-linked substrates was
observed after several months storage.
Ub-Thr and Ub-Ser were prepared chemoenzymatically in reaction buffer
consisting of Na2PO4 (40 mM), NaCl (150 mM), MgCl2 (5 mM), Nα-acetyl-
L-threonine (50 mM), E1 Uba1 (500 nM), E2 UBE2D3 (10 μM), GST-MYCBP2cat
(5 μM), Ub (50 μM), ATP (5 mM), and TCEP (0.5 mM) in a volume of 2.33 mL.
The reaction was incubated at 37 °C for 1 to 2 h, and Ub-Thr was purified
by RP-HPLC using a 20 to 50% gradient over 60 min (buffer A was 0.1%
trifluoroacetic acid [TFA] in H2O, and buffer B was 0.1% TFA in acetonitrile).
Substrates were reconstituted as described for Ub-Lys, and ester linkages
were found to be stable in PBS at −80 °C for at least 6 mo.
To prepare Ub-Glutathione, Ub carrying a mercaptoethanesulfonic acid
group was initially generated chemoenzymatically. Then, 1 mL of the che-
moenzymatic reaction (20 mM Na2HPO4, pH 8, 10 mM MgCl2, 10 mM ATP,
467 μM Ub, 100 mM sodium mercaptoethanesulfonate, 250 nM E1) was in-
cubated for 4 h at 37 °C. Ub-MESNA thioester was quantitatively produced
and purified by semipreparative HPLC on a Dionex Ultimate 3000 System
using a 250 mm × 21.2 mm Thermo Biobasic C4 column. A gradient of 10%
mobile phase A to 80% mobile phase B over 30 min was applied (mobile
phase A = 0.1% TFA in H2O, and buffer B = 0.1% TFA in acetonitrile).
Fractions containing Ub-MESNA were then freeze-dried, yielding 3.7 mg.
Ub-MESNA. (3.7 mg). was then dissolved in denaturing buffer containing
reduced glutathione (200 mM Na2HPO4, pH 7.5, 6 M guanidinium chloride,
100 mM glutathione). The reaction was agitated for 2 h at 23 °C, allowing
transthioesterification to proceed. Ub-Glutathione was then purified by
semipreparative HPLC using a gradient of 20% buffer A to 70% buffer B
























JOSD1 W100A JOSD1 W101F
JOSD1 W100F W101F






















































Fig. 6. Determinants of MJD DUB esterase selectivity. (A) Superposition of
the active site for a JOSD1 homology model with that of the ATXN3L:Ub
complex (PDB ID code 3O65). (B) Sequence alignment for the MJD DUB class.
Catalytic residues and those proposed to be important for esterase activity
are highlighted. (C) FP assay demonstrating that JOSD1 esterase activity is
dependent on canonical catalytic residues and the hydrophobic W100 resi-
due. Concentrations of Ub-Thr-TAMRA and JOSD1 variant were 250 nM and
500 nM, respectively. (D) Introduction of a W100F mutation into JOSD1 re-
duced activity by approximately sevenfold whereas a W101F mutant
retained WT levels of activity. Mutations had no discernible effect on iso-
peptidase activity. Concentrations of Ub-Thr-TAMRA/Ub-Lys-TAMRA-Gly and
JOSD1 variant were 250 nM and 750 nM, respectively.
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over 60 min. Fractions containing Ub-Glutathione were determined by LC-
MS, and product was freeze-dried (yield ∼1 mg) and stored at −20 °C.
Synthesis of Ubiquitinated PeptideModel Substrates.Ac-EGKGN-NH2, Ac-EGTGN-NH2,
and Ac-EGSGN-NH2 were purchased from Bio-synthesis and resuspended in
water to 250 mM final, the pH adjusted to 7 to 8 using 0.4 M NaOH. Ub-
EGKGN and Ub-EGTGN/Ub-EGSGN were prepared chemoenzymatically us-
ing RNF4 and MYCBP2, respectively. RNF4 (10 μM) or GST-MYCBP2cat (5)
(10 μM) were diluted in reaction buffer consisting of Na2PO4 (40 mM), NaCl
(150 mM), MgCl2 (5 mM), Nα-acetyl-L-threonine (50 mM), E1 Uba1 (500 nM),
E2 UBE2D3 (10 μM), Ub (50 μM), ATP (5 mM), and TCEP (0.5 mM). Reaction
was incubated at 37 °C for 1 to 2 h, and Ub-EGKGN and Ub-EGTGN were
purified by RP-HPLC using a 20 to 50% gradient over 60 min (buffer A was
0.1% TFA in H2O, and buffer B was 0.1% TFA in acetonitrile).
Synthesis of Ub-Lys-TAMRA and Ub-Thr-TAMRA Fluorescent Substrates. Initially,
threonine and lysine were functionalized at the Nα position with TAMRA. A
10-fold molar excess of amino acid [L-threonine or N«-(t-butyloxycarbonyl-)
L-lysine] and N,N-diisopropylethylamine (DIEA) was mixed with 5/6 TAMRA-
OSu (C1171; Thermo Fisher) in DMSO. After agitation for 24 h, reactions
were diluted to 10% DMSO with H2O, and products were purified by RP-
HPLC and lyophilized, yielding threonine-TAMRA and N«-(t-butylox-
ycarbonyl)-Lys-TAMRA. To remove the t-butyloxycarbonyl protecting group
from the lysine product, material was dissolved in the minimum volume of
dichloromethane, which was subsequently diluted to 60% with TFA. Solvent
was removed with a stream of air and repurified by RP-HPLC, yielding Lys-
TAMRA. Fluorescent Ub-Lys-TAMRA and Ub-Thr-TAMRA substrates were
prepared as described for Ub-Lys and Ub-Thr, but Nα-acetyl-L-lysine and
L-threonine were substituted for Lys-TAMRA and Thr-TAMRA, respectively.
FP Assay. Ub-K/T-TAMRA (final concentration 0.250 to 40 μM for kinetic
calculation, 0.250 μM for standard assay) were diluted in FP buffer (50 mM
Tris·HCl, pH 7.5, 150 mM NaCl, 1 mM DTT, 0.01% BSA) aliquotted into a
384-well plate (black low volume, round bottom; Corning). DUBs were di-
luted at the indicated final concentration in FP buffer and added into each
well. FP decay was measured with a cycle time of 30 s for 60 cycles at 30 °C
using a plate reader (Pherarastar; BMG Labtech). Normalized parallel and
perpendicular fluorescence intensities were used for further calculations.
Graphpad Prism 8.0 was used to fit the data into Michaelis–Menten equa-
tions and calculate kinetic parameters. Observed first order rate constants
(kobs) were approximated using the half-life equation t1/2 = ln2/kobs.
Gel-Based Ubiquitinated Peptide Cleavage Assay. DUBs (750 nM final con-
centration) and Ub-EGKGN/Ub-EGTGN (5 μM final concentration) were di-
luted in 50 mM Tris·HCl, pH 7.0, 50 mM NaCl2, and 1 mM DTT. Reaction was
incubated for the indicated time points at 30° and stopped by adding 1×
final LDS-NuPAGE sample buffer. Samples were run on 1-mm, 4 to 12% Bis-
Tris Protein Gels for 45 min at 200 V and blue Coomassie stained. Silver
staining was also carried out in accordance with manufacturer protocols
(Thermo Scientific Pierce Silver Stain Kit).
Target Spotting and MALDI Mass Spectrometry Analysis. The DHAP matrix
solution was prepared as previously described (17). Briefly, 7.6 mg of DHAP
were resuspended in 375 μL of LC-MS grade ethanol and 125 μL of an
aqueous solution of 25 mg/mL diammoniumhydrogen citrate (25102-500G-R;
Sigma Aldrich). MALDI-target spotting and MS analysis were performed as
previously described (54). Briefly, a Mosquito nanoliter dispenser (TTP Lab-
tech, Hertfordshire, UK) was employed to mix 1.2 μL of each reaction with
1.2 μL of DHAP matrix solution. Then, 200 nL of matrix/assay mixture from
each sample were spotted onto a 1536 AnchorChip MALDI target. Spotted
MALDI-targets were air dried prior to MALDI-TOF MS analysis. All samples
were acquired as previously reported on a Rapiflex MALDI-TOF mass spec-
trometer (Bruker Daltonics, Bremen, Germany) equipped with Compass for
FlexSeries 2.0, FlexControl, and FlexAnalysis software (version 4.0). Peak in-
tensities were exported as. csv file using FlexAnalysis. An in-house Windows
batch script was used to report peak intensities into an Excel grid with the
same geometry as for the MALDI-target. Because of the intrinsic variability of
MALDI-TOF ionization, for diUb substrates, the mono Ub product was quan-
tified by reference to an internal standard consisting of 15N-labeled Ub,
allowing determination of percent cleavage (17). For Ub-W or Ub-Glutathione
substrates, the mono Ub product was also quantified by reference to the
isotopic standard, but, to account for the single molecule of Ub generated
upon cleavage of a substrate molecule, the following equation was applied:
% Ub  Substrate  Cleavage =   ((Area Ub)=(Area15N Ub)
× [15N Ub])=[Ub  Substrate] × 100
As the mass of the Ub-Thr substrate overlapped with the 15N-labeled Ub,
standard curves were generated for Ub-Lys and Ub-Thr using defined
product/substrate ratios allowing determination of percent of cleavage. In
the case of Ub-Ser, the standard curve generated for Ub-Thr was applied.
MALDI-TOF DUB Assay. Enzymes and substrates were freshly prepared in the
reaction buffer (40 mM Tris·HCl, pH 7.6, 5 mM DTT, 0.005% BSA). DUBs were
diluted at the indicated concentrations (SI Appendix, Table S1), and 5.8 μL of
reaction buffer and 3 μL of diluted DUBs were aliquotted in a Greiner
384-well plate, flat round bottom, low binding. Then, 1.2 μL of either Ub
dimers, Ub-W, Ub-Lys, Ub-Thr, Ub-Ser, or Ub-Glutathione was added to the
reaction mixture at final concentration of 1.4, 2.75, 2.75, 2.75, 2.75, and
2.75 μM, respectively. DUBs tested for their ability to cleave Ub-Glutathione
were previously dialyzed against 1× PBS buffer supplemented with 0.5 mM
TCEP. DTT was also withheld from the DUB assay buffer. The reaction was
incubated at 30 °C and stopped by adding 2.5 μL of 10% TFA at the indicated
time points. 15N-labeled Ub was added as internal standard only to the re-
action controls using Ub dimers, Ub-W, or Ub-Glutathione as substrate.
Cellular Assessment of Ubiquitin Ester Stability. E2Ser∼Ub was prepared using
a Cys85Ser mutant of an N-terminal His-tagged clone of the E2 enzyme
UbcH5c. Ester loading was carried out enzymatically, and product was pu-
rified as previously described, with the exception that the reaction was
performed at pH 7.5 (39). Low passage HEK293 cells (106) were resuspended
in 30 μL of Neon Electroporation Buffer R containing 26 μg (3 μL of 8.6 mg/mL
stock) E2Ser∼Ub. The mixture (20 μL) was directly transferred into prewarmed
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% (vol/
vol) fetal bovine serum (FBS), 2.0 mM ʟ-glutamine, and lacking antibiotics,
and incubated at 37 °C/5% CO2, while another 20 μL was electroporated
using the Neon Transfection System (2 × 1,400 V, 20 ms) in 10-μL tips, before
transfer into prewarmed media and incubation at 37 °C/5% CO2. The ex-
periment was replicated in parallel, using HEK293 pretreated with MG132
(20 μM) for 30 min, and cells were subsequently incubated in media con-
taining 20 μM MG132. Then, 600,000 cells were collected at intervals post-
electroporation, washed thrice in ice-cold PBS, and lysed in ice-cold lysis
buffer (50 mM Tris·HCl, pH 7.5, 10 mM sodium 2-glycerophosphate, 50 mM
sodium fluoride, 5.0 mM sodium pyrophosphate, 1.0 mM sodium orthova-
nadate, 0.27 M sucrose, 50 mM NaCl, 0.2 mM phenylmethanesulfonyl fluo-
ride [PMSF], 1.0 mM benzamidine, 10 mM TCEP, 1% Nonidet P-40) on ice for
30 min. Lysates were clarified by centrifugation at 4 °C for 20 min at 21,100 ×
g. Supernatants were collected, and protein concentration was determined
by Bradford assay. Immunoblotting was carried out, and membranes were
probed with antibodies against the His tag on the E2 protein in E2Ser∼Ub
(631212; Clontech) and tubulin (66031-1-Ig; Proteintech) as a loading control.
UBE2J2-Based DUB Activity Assay. A UBE2J2 automodification reaction was
performed by incubating E1 (200 nM), Ub (50 μM), and recombinant His-
UBE2J2 (10 μM) (5) in reaction Buffer (1× PBS, 20 mM MgCl2, 2 mM ATP,
1 mM TCEP) for 30 min at 30 °C in a final volume of 100 μL. Compound 1 E1
inhibitor was added at a final concentration of 25 μM, and the reaction was
incubated for 15 min at 30 °C. The reaction was then subaliquotted and
treated with either JOSD1 (3 μM), USP2 (3 μM), or 1× PBS buffer for 30 min at
30 °C. Reactions were stopped by addition of 4× lithium dodecyl sulfate
loading buffer (Thermo Fisher Scientific) plus BME and supplemented with
either water or hydroxylamine (0.5 M). Samples where incubated for 30 min at
37 °C and resolved on a 4 to 12% Bis-Tris gel at 125 V for 1.4 h. Protein
bands were either visualized by Coomassie stain or by standard Western
blot procedure (anti-ubiquitin antibody, cat. no. 646302, monoclonal, mouse,
0.1 μg/mL; BioLegend).
Transient Overexpression of JOSD1 in HEK293 Cells. HEK293 cells (106) were
seeded in a 10-cm dish and incubated for 16 h at 37 °C, 5% CO2. At ∼70%
confluency, JOSD1-HA plasmid (7 μg; vector pCMV-HA-C) was transfected
using Lipofectamine 2000, and cells were incubated for 24 h. Proteasome
inhibitor MG-132 (10 μM, 474790; Millipore-Sigma) was added to cells 5 h
before lysis. Cells were lysed in buffer (50 mM Tris·HCl, 250 mM NaCl2, 0.1%
Nonidet P-40) supplemented with cOmplete, Mini, (ethylenedinitrilo)tetra-
acetic acid (EDTA)-free Protease Inhibitor Tablets (11836170001; Roche),
benzamidine (1 mM), PMSF (0.25 mM), and MG132 (10 μM). Lysates were
clarified by centrifugation and quantified by Bradford assay. JOSD1 detection
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by immunoblotting was performed using JOSD1 monoclonal antibody
(OTI3B11; Thermo Fisher Scientific) and standard immunoblotting procedures.
Data Availability. All study data are included in the article and SI Appendix.
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